The U.S. Preventive Services Task Force’s new recommendation statement on the use of statin therapy for primary prevention in adults aged 40 to 75 years with no history of CVD is similar to its 2016 recommendations.The USPSTF continues to recommend statins for the primary prevention of CVD in patients aged 40 to 75 years with at least one CVD risk factor and 10% or greater 10-year risk for
This 2022 Recommendation Statement from the US Preventive Services Task Force recommends screening for syphilis infection in persons who are at increased risk f
This 2022 Recommendation Statement from the US Preventive Services Task Force concludes that the current evidence is insufficient to assess the balance of benef
The U.S. Preventive Services Task Force (USPSTF) has issued a Recommendation Statement, relating to Statin Use for the Primary Prevention of Cardiovascular Disease in Adults, published in the Journal of American Medical Association (JAMA). This recommendation replaces the 2016 USPSTF recommendation on statin use for the primary prevention of CVD and is generally consistent with that recommendation.
The new statement invites comparison with the more comprehensive 2018 ACC/AHA-multisociety statin guidelines. A slew of editorials across several journals do just that.